(MDXG) MiMedx - Ratings and Ratios
Allograft, Wound, Graft, Membrane, Tissue
MDXG EPS (Earnings per Share)
MDXG Revenue
Description: MDXG MiMedx
MiMedx Group Inc (NASDAQ:MDXG) is a biotechnology company listed on the NASDAQ stock exchange. The companys stock performance is characterized by a current price of $7.31, with various moving averages indicating a potential trend reversal. To assess the viability of MDXG as a trading opportunity, its essential to examine key economic drivers and KPIs.
The biotechnology industry is heavily influenced by factors such as R&D pipeline strength, regulatory approvals, and market demand for innovative treatments. MiMedxs financial health, as reflected in its market capitalization of $1.038 billion, suggests a considerable presence in the industry. The price-to-earnings ratio of 33.43 and forward P/E of 19.53 indicate that investors have certain growth expectations, which may be driven by the companys product portfolio and its ability to expand into new markets.
A critical aspect of evaluating MDXGs potential is analyzing its return on equity (RoE) of 16.22%, which signifies the companys ability to generate profits from shareholder equity. This metric, combined with the companys P/E ratio, suggests that investors are willing to pay a premium for MDXGs earnings, potentially due to growth prospects or the companys competitive positioning within the biotechnology sector.
To deconstruct MDXGs trading opportunity further, its crucial to monitor key performance indicators such as revenue growth, gross margin expansion, and the success of its product pipeline. The companys ability to navigate regulatory landscapes, particularly in the biotechnology industry, will also be a significant driver of its stock performance. By focusing on these fundamental drivers and maintaining a data-driven approach, traders can better assess the optimal entry and exit points for MDXG.
MDXG Stock Overview
| Market Cap in USD | 1,053m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2007-08-22 |
MDXG Stock Ratings
| Growth Rating | 40.4% |
| Fundamental | 77.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -5.75% |
| Analyst Rating | 5.0 of 5 |
MDXG Dividends
Currently no dividends paidMDXG Growth Ratios
| Growth Correlation 3m | 78.8% |
| Growth Correlation 12m | -12.2% |
| Growth Correlation 5y | -0.4% |
| CAGR 5y | 29.40% |
| CAGR/Max DD 3y | 0.73 |
| CAGR/Mean DD 3y | 1.87 |
| Sharpe Ratio 12m | -0.09 |
| Alpha | -7.96 |
| Beta | 0.992 |
| Volatility | 40.64% |
| Current Volume | 393k |
| Average Volume 20d | 393k |
| Stop Loss | 6.7 (-3.9%) |
| Signal | -0.65 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (32.2m TTM) > 0 and > 6% of Revenue (6% = 21.8m TTM) |
| FCFTA 0.21 (>2.0%) and ΔFCFTA 0.63pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 46.89% (prev 33.49%; Δ 13.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 58.1m > Net Income 32.2m (YES >=105%, WARN >=100%) |
| Net Debt (-100.4m) to EBITDA (49.8m) ratio: -2.02 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (149.3m) change vs 12m ago 0.28% (target <= -2.0% for YES) |
| Gross Margin 81.45% (prev 83.30%; Δ -1.85pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 139.6% (prev 147.9%; Δ -8.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.88 (EBITDA TTM 49.8m / Interest Expense TTM 4.02m) >= 6 (WARN >= 3) |
Altman Z'' 3.09
| (A) 0.59 = (Total Current Assets 220.9m - Total Current Liabilities 50.3m) / Total Assets 291.1m |
| (B) -0.26 = Retained Earnings (Balance) -74.6m / Total Assets 291.1m |
| (C) 0.17 = EBIT TTM 43.8m / Avg Total Assets 260.6m |
| (D) -1.00 = Book Value of Equity -74.5m / Total Liabilities 74.5m |
| Total Rating: 3.09 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.32
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 6.44% = 3.22 |
| 3. FCF Margin 16.86% = 4.22 |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda 0.37 = 2.39 |
| 6. ROIC - WACC 5.22% = 6.52 |
| 7. RoE 16.22% = 1.35 |
| 8. Rev. Trend 91.88% = 4.59 |
| 9. Rev. CAGR 14.66% = 1.83 |
| 10. EPS Trend 27.89% = 0.70 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of MDXG shares?
Over the past week, the price has changed by -2.79%, over one month by -1.97%, over three months by +16.36% and over the past year by +12.06%.
Is MiMedx a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MDXG is around 6.17 USD . This means that MDXG is currently overvalued and has a potential downside of -11.48%.
Is MDXG a buy, sell or hold?
- Strong Buy: 5
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MDXG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.2 | 75% |
| Analysts Target Price | 12.2 | 75% |
| ValueRay Target Price | 6.9 | -0.4% |
Last update: 2025-09-11 04:43
MDXG Fundamental Data Overview
CCE Cash And Equivalents = 118.9m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 33.9048
P/E Forward = 19.5313
P/S = 2.8959
P/B = 4.8973
P/EG = 2.97
Beta = 1.744
Revenue TTM = 363.8m USD
EBIT TTM = 43.8m USD
EBITDA TTM = 49.8m USD
Long Term Debt = 17.2m USD (from longTermDebt, last quarter)
Short Term Debt = 1.25m USD (from shortTermDebt, last quarter)
Debt = 18.5m USD (Calculated: Short Term 1.25m + Long Term 17.2m)
Net Debt = -100.4m USD (from netDebt column, last quarter)
Enterprise Value = 953.1m USD (1.05b + Debt 18.5m - CCE 118.9m)
Interest Coverage Ratio = 10.88 (Ebit TTM 43.8m / Interest Expense TTM 4.02m)
FCF Yield = 6.44% (FCF TTM 61.3m / Enterprise Value 953.1m)
FCF Margin = 16.86% (FCF TTM 61.3m / Revenue TTM 363.8m)
Net Margin = 8.84% (Net Income TTM 32.2m / Revenue TTM 363.8m)
Gross Margin = 81.45% ((Revenue TTM 363.8m - Cost of Revenue TTM 67.5m) / Revenue TTM)
Tobins Q-Ratio = -12.80 (set to none) (Enterprise Value 953.1m / Book Value Of Equity -74.5m)
Interest Expense / Debt = 4.00% (Interest Expense 738.0k / Debt 18.5m)
Taxrate = 26.70% (15.3m / 57.3m)
NOPAT = 32.1m (EBIT 43.8m * (1 - 26.70%))
Current Ratio = 4.39 (Total Current Assets 220.9m / Total Current Liabilities 50.3m)
Debt / Equity = 0.09 (Debt 18.5m / last Quarter total Stockholder Equity 216.6m)
Debt / EBITDA = 0.37 (Net Debt -100.4m / EBITDA 49.8m)
Debt / FCF = 0.30 (Debt 18.5m / FCF TTM 61.3m)
Total Stockholder Equity = 198.4m (last 4 quarters mean)
RoA = 11.05% (Net Income 32.2m, Total Assets 291.1m )
RoE = 16.22% (Net Income TTM 32.2m / Total Stockholder Equity 198.4m)
RoCE = 20.29% (Ebit 43.8m / (Equity 198.4m + L.T.Debt 17.2m))
RoIC = 14.77% (NOPAT 32.1m / Invested Capital 217.1m)
WACC = 9.55% (E(1.05b)/V(1.07b) * Re(9.67%)) + (D(18.5m)/V(1.07b) * Rd(4.00%) * (1-Tc(0.27)))
Shares Correlation 3-Years: 78.79 | Cagr: 2.53%
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.13% ; FCFE base≈55.6m ; Y1≈67.8m ; Y5≈112.3m
Fair Price DCF = 9.70 (DCF Value 1.44b / Shares Outstanding 148.0m; 5y FCF grow 23.31% → 3.0% )
Revenue Correlation: 91.88 | Revenue CAGR: 14.66%
Rev Growth-of-Growth: -6.50
EPS Correlation: 27.89 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -199.7
Additional Sources for MDXG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle